Thus, we first assessed subcellular levels of TDP-43 in astrocytes from AD, FTD, and control (nondementia) cases by performing quantitative immunofluorescent labeling for TDP-43 and the astrocyte marker glial fibrillary acidic protein (GFAP) in postmortem human hippocampal sections. This evidence concerns the gene GFAP and Alzheimer disease.